Trial Profile
Comparative Assessment of Tedizolid Tissue Penetration and Pharmacokinetic Profile Between Diabetic Patients With Wound Infections and Healthy Volunteers Via In Vivo Microdialysis
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 12 May 2022
Price :
$35
*
At a glance
- Drugs Tedizolid (Primary)
- Indications Nosocomial pneumonia; Skin and soft tissue infections
- Focus Therapeutic Use
- Acronyms TZD MicroD
- 31 Jul 2018 Status changed from recruiting to completed.
- 25 Apr 2017 Results of pharmacokinetic data from diabetic patients with lower limb infection (n=6) presented at the 27th European Congress of Clinical Microbiology and Infectious Diseases
- 23 Feb 2017 Planned End Date changed from 1 Dec 2016 to 1 Dec 2017.